Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947128 | 0.80 | CYP2A6 (1.00) | CYP2A6CA2MAPTKEAP1NFE2L2 | |
| SCHEMBL7141321 | 0.80 | CYP2A6 (0.67) | CYP2A6CA2MAPTTP53KEAP1 | |
| SCHEMBL4255979 | 0.79 | CYP2A6 (0.71) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL8431982 | 0.78 | CYP2A6 (0.63) | CYP2A6CA2KEAP1NFE2L2 | |
| SCHEMBL2217042 | 0.77 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL29414360 | 0.77 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3576292 | 0.77 | CYP2A6 (1.00) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL3742332 | 0.77 | CYP2A6 (0.69) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL31588788 | 0.76 | CYP2A6 (0.67) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL274426 | 0.75 | CYP2A6 (0.60) | CYP2A6CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014113485-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-5792763-A | MIGRAINES; ANALGESICS; DISEASES LINKED TO DECREASED NEUROTRANMISSION OF SEROTONIN IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1998015545-A1 | NEW SEROTONIN 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0835869-A2 | New serotonin 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | CYP2A6 3293/4885CA2 783/4885CSNK2A1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.